Nycomed's intranasal fentanyl recommended for EU marketing
This article was originally published in Scrip
Executive Summary
Instanyl, Nycomed's intranasal formulation of fentanyl citrate, has been recommended for centralised marketing approval in the EU for the treatment of breakthrough pain in cancer patients who receive chronic opioid treatment for the management of their background pain.